KPTI

MKT CAP:$74M

Karyopharm Therapeutics Inc.

Market Cap

$74M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$8.75+$1.56 (+21.70%)

Apr 23, 2026

Company Details

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and comm...

CEO

Richard A. Paulson

IPO Date

Nov 6, 2013

Website

www.karyopharm.com

Key Metrics TTM

Revenue

$146M

+0.6% YoY

Net Income

-$196M

EPS (Diluted)

-$16.60

Free Cash Flow

-$75M

Revenue / Share

$8.12

Gross Margin

95.9%

Operating Margin

-62.1%

Net Margin

-134.2%

FCF Margin

-51.6%

P/S

0.5x

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Feb 12, 2026

$146M+0.6%EPS -$17.93

Q4 2025

Feb 12, 2026

$34M+11.6%EPS -$5.69

Q3 2025

Nov 3, 2025

$44M+13.6%EPS -$3.82

Q2 2025

Aug 11, 2025

$38M-11.4%EPS -$4.32

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$48M	$46M	-$35M
Q2 22	$40M	$39M	-$43M
Q3 22	$36M	$35M	-$31M
Q4 22	$34M	$32M	-$34M
Q1 23	$39M	$37M	-$31M
Q2 23	$38M	$36M	-$30M
Q3 23	$36M	$35M	-$31M
Q4 23	$34M	$32M	-$38M
Q1 24	$33M	$31M	-$34M
Q2 24	$43M	$41M	-$28M
Q3 24	$39M	$37M	-$26M
Q4 24	$31M	$29M	-$31M
Q1 25	$30M	$29M	-$33M
Q2 25	$38M	$37M	-$24M
Q3 25	$44M	$42M	-$15M
Q4 25	$34M	$33M	-$18M

Valuation

Quarter	P/S	P/E
Q1 22	0.3x	—
Q2 22	0.3x	—
Q3 22	0.3x	—
Q4 22	0.5x	—
Q1 23	0.5x	—
Q2 23	0.5x	—
Q3 23	0.5x	—
Q4 23	0.5x	—
Q1 24	0.5x	—
Q2 24	0.5x	—
Q3 24	0.5x	—
Q4 24	0.5x	—
Q1 25	0.5x	—
Q2 25	0.5x	—
Q3 25	0.5x	—
Q4 25	0.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$59M	-$59M
Q2 22	-$35M	-$35M
Q3 22	-$28M	-$28M
Q4 22	-$27M	-$27M
Q1 23	-$19M	-$19M
Q2 23	-$26M	-$26M
Q3 23	-$30M	-$30M
Q4 23	-$19M	-$19M
Q1 24	-$44M	-$44M
Q2 24	-$38M	-$38M
Q3 24	-$19M	-$19M
Q4 24	-$26M	-$26M
Q1 25	-$39M	-$39M
Q2 25	-$19M	-$19M
Q3 25	-$6M	-$6M
Q4 25	-$12M	-$12M

Capital Expenditures

Quarter	CapEx
Q1 22	$79.0K
Q2 22	$0
Q3 22	$39.0K
Q4 22	$79.0K
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$195.0K
Q2 24	$0
Q3 24	$0
Q4 24	$53.0K
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+104.9%	+8.8%
Q2 22	+75.6%	+15.3%
Q3 22	-4.1%	-17.8%
Q4 22	-73.4%	-15.0%
Q1 23	-18.8%	-15.4%
Q2 23	-5.3%	-18.7%
Q3 23	-0.4%	+0.4%
Q4 23	+0.5%	+6.1%
Q1 24	-14.4%	-3.9%
Q2 24	+13.9%	+5.6%
Q3 24	+7.7%	-3.3%
Q4 24	-9.5%	-13.6%
Q1 25	-9.4%	-5.4%
Q2 25	-11.4%	-12.1%
Q3 25	+13.6%	-8.9%
Q4 25	+11.6%	-16.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$7M	15.4%
Q2 22	$15M	38.0%
Q3 22	$7M	18.8%
Q4 22	$6M	18.4%
Q1 23	$5M	13.9%
Q2 23	$6M	16.1%
Q3 23	$5M	14.1%
Q4 23	$5M	15.4%
Q1 24	$5M	15.0%
Q2 24	$5M	12.6%
Q3 24	$4M	10.8%
Q4 24	$4M	12.7%
Q1 25	$4M	11.9%
Q2 25	$4M	10.0%
Q3 25	$0	0.0%
Q4 25	$4M	11.5%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$42M	$39M	—
Q2 22	$44M	$37M	—
Q3 22	$31M	$35M	—
Q4 22	$31M	$35M	—
Q1 23	$32M	$36M	—
Q2 23	$31M	$34M	—
Q3 23	$36M	$31M	—
Q4 23	$39M	$31M	—
Q1 24	$35M	$30M	—
Q2 24	$38M	$31M	—
Q3 24	$36M	$28M	—
Q4 24	$33M	$27M	—
Q1 25	$35M	$27M	—
Q2 25	$33M	$28M	—
Q3 25	$31M	$27M	—
Q4 25	$28M	—	$23M

Revenue Segments

Quarter	License And Other	Product
Q1 22	$19M	$28M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$153M	$52M	$205M
Q2 22	$82M	$89M	$171M
Q3 22	$71M	$77M	$148M
Q4 22	$135M	$143M	$278M
Q1 23	$84M	$176M	$260M
Q2 23	$81M	$156M	$237M
Q3 23	$44M	$165M	$208M
Q4 23	$52M	$139M	$191M
Q1 24	$31M	$118M	$149M
Q2 24	$85M	$67M	$152M
Q3 24	$73M	$61M	$134M
Q4 24	$62M	$46M	$109M
Q1 25	$39M	$31M	$70M
Q2 25	$39M	$13M	$52M
Q3 25	$38M	$8M	$46M
Q4 25	$61M	$3M	$64M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	78M	-10.7%	+4.1%
Q2 22	80M	+2.7%	+5.9%
Q3 22	80M	+0.7%	+6.3%
Q4 22	90M	+12.1%	+3.5%
Q1 23	8M	-91.6%	-90.2%
Q2 23	114M	+1409.6%	+43.4%
Q3 23	8M	-93.3%	-90.5%
Q4 23	8M	+0.3%	-91.5%
Q1 24	8M	+0.6%	+1.7%
Q2 24	10M	+33.8%	-91.0%
Q3 24	8M	-19.0%	+9.3%
Q4 24	8M	+0.7%	+9.7%
Q1 25	8M	+0.9%	+10.0%
Q2 25	9M	+1.8%	-16.3%
Q3 25	9M	+0.6%	+4.0%
Q4 25	18M	+107.4%	+114.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$107.9K	442
Q2 22	$89.8K	442
Q3 22	$81.8K	442
Q4 22	$87.2K	385
Q1 23	$100.5K	385
Q2 23	$97.6K	385
Q3 23	$93.5K	385
Q4 23	$103.8K	325
Q1 24	$101.9K	325
Q2 24	$131.6K	325
Q3 24	$119.3K	325
Q4 24	$109.5K	279
Q1 25	$107.6K	279
Q2 25	$135.9K	279
Q3 25	$157.9K	279
Q4 25	$1.9K	18K

Revenue / Employee